About
Robert Karr has broad experience in the drug discovery and development process, including discovery/preclinical research, IND preparation, interactions with the FDA, the design and conduct of clinical trials, and investor relations. He currently serves as CSO of Tioma Therapeutics and previously served as President & CEO of Indalo (then called Antegrin Therapeutics) from 2012-2015. Prior roles have included President of Idera Pharmaceuticals, Senior Vice President of Strategic Management at Pfizer, and Vice President of Research and Development Strategy at Warner-Lambert. Dr. Karr received his B.S. (Honors) from Southwestern University in 1971 and his M.D (with highest honors) from the University of Texas Medical Branch in 1975.
Position in the VCSift Database
- • 9 investors hold the Founder, Chief Executive Officer & President role in VCSift. Robert Karr is one of them.
- • 257 investors are based in St Louis, Missouri, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- St Louis, US
Contact Information
Find more investors like Robert
Search Investors